evidence: Previous studies have shown that the HPV vaccine is effective at reducing the risk of cervical cancer, however, there has been limited evidence linking it to a decreased likelihood of developing other HPV-related cancers since the introduction of the first version of the vaccine in 2006. [...] Previous research pertaining to HPV-vaccination has primarily focused on outcomes related to cervical cancer. It is the fourth most common cancer globally with about 660,000 new cases diagnosed annually with nearly 350,000 deaths per the World Health Organization. This study examines the HPV-vaccinated persons’ risk of developing cancers of the head and neck, anal areas, penis, vulva, vagina, and cervix. This study also aims to examine the HPV vaccine’s impact on need for surgical treatment of cancer and pre-cancerous lesions. [...] Females vaccinated for HPV had a lower risk of developing cervical cancer (7.4 cases per 100,000 vaccinated patients vs. 10.4 per 100,000 unvaccinated patients) and a lower risk of developing all HPV-related cancers compared to unvaccinated females (11.5 cases per 100,000 vaccinated patients vs. 15.8 per 100,000 unvaccinated patients). However, odds of developing head and neck cancers and vulvar or vaginal cancer were not significantly different in vaccinated females compared to those who had not received the vaccine.